Tides Express | Anjin AMG133 Approved for Clinical Use in China
Editor of the Peptide Biochemistry Content Team On November 20, 2023, the CDE official website announced that Amgen’s Class 1 new drug AMG 133 has obtained implied clinical trial approval in China and is intended to be developed for weight control. AMG 133 is a potential “first in class” antibody peptide conjugate drug under development,…